{"title":"Perineural invasion in digestive tract tumors: Immune system interactions and therapeutic strategies.","authors":"Jia-Yu Pang, Rong-Yao Jin, Han-Xiao Zhang, Ying-Hua Zhang, Xin-Yue Wei, Wen-Bo Cao, Yi-Xiao Chen, Jun-Ling Wang, Sai-Jun Mo","doi":"10.5306/wjco.v17.i2.113674","DOIUrl":null,"url":null,"abstract":"<p><p>Digestive tract tumors represent a substantial global public health challenge, accounting for elevated morbidity and mortality rates. Perineural invasion (PNI), the spread of tumor cells along nerve fibers, has emerged as a key driver of aggressiveness and a poor prognosis. This study systematically reviews the complex, underexplored interplay between PNI and antitumor immunity in gastrointestinal cancers. By analyzing immune-related components (the programmed cell death protein 1/programmed death ligand 1 axis, T cell subsets, tumor-associated macrophages, and other immune checkpoints), it reveals PNI disrupts immune balance: It suppresses T-cell activity <i>via</i> programmed death ligand 1/programmed cell death protein 1 binding, skews T-cell differentiation to reduce antitumor efficacy and boost immunosuppression, and polarizes macrophages to aid tumor progression. These findings provide novel insights into how PNI reshapes the tumor immune microenvironment and promotes metastatic behavior, establishing a framework for prioritizing immunotherapeutic targets to inform precision treatment strategies.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"17 2","pages":"113674"},"PeriodicalIF":3.6000,"publicationDate":"2026-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12968545/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World journal of clinical oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5306/wjco.v17.i2.113674","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Digestive tract tumors represent a substantial global public health challenge, accounting for elevated morbidity and mortality rates. Perineural invasion (PNI), the spread of tumor cells along nerve fibers, has emerged as a key driver of aggressiveness and a poor prognosis. This study systematically reviews the complex, underexplored interplay between PNI and antitumor immunity in gastrointestinal cancers. By analyzing immune-related components (the programmed cell death protein 1/programmed death ligand 1 axis, T cell subsets, tumor-associated macrophages, and other immune checkpoints), it reveals PNI disrupts immune balance: It suppresses T-cell activity via programmed death ligand 1/programmed cell death protein 1 binding, skews T-cell differentiation to reduce antitumor efficacy and boost immunosuppression, and polarizes macrophages to aid tumor progression. These findings provide novel insights into how PNI reshapes the tumor immune microenvironment and promotes metastatic behavior, establishing a framework for prioritizing immunotherapeutic targets to inform precision treatment strategies.
期刊介绍:
The WJCO is a high-quality, peer reviewed, open-access journal. The primary task of WJCO is to rapidly publish high-quality original articles, reviews, editorials, and case reports in the field of oncology. In order to promote productive academic communication, the peer review process for the WJCO is transparent; to this end, all published manuscripts are accompanied by the anonymized reviewers’ comments as well as the authors’ responses. The primary aims of the WJCO are to improve diagnostic, therapeutic and preventive modalities and the skills of clinicians and to guide clinical practice in oncology. Scope: Art of Oncology, Biology of Neoplasia, Breast Cancer, Cancer Prevention and Control, Cancer-Related Complications, Diagnosis in Oncology, Gastrointestinal Cancer, Genetic Testing For Cancer, Gynecologic Cancer, Head and Neck Cancer, Hematologic Malignancy, Lung Cancer, Melanoma, Molecular Oncology, Neurooncology, Palliative and Supportive Care, Pediatric Oncology, Surgical Oncology, Translational Oncology, and Urologic Oncology.